Zymeworks announces participation in investor conferences, highlighting its pipeline of biotherapeutics targeting difficult-to-treat diseases.
Quiver AI Summary
Zymeworks Inc., a clinical-stage biotechnology company based in Vancouver, is focused on developing novel biotherapeutics for challenging diseases such as cancer and autoimmune conditions. The company announced its participation in several upcoming investor conferences, including one-on-one meetings and discussions at the Oppenheimer Healthcare Conference on February 11, Citi's Oncology Leadership Summit on February 20, and the B. Riley Securities Conference on February 28. Zymeworks has made significant advancements, including the accelerated FDA approval of Ziihera®, a biotherapeutic for HER2-positive biliary tract cancer, and is conducting ongoing clinical trials for other candidates in its pipeline. The firm aims to leverage its proprietary technology and strategic partnerships to enhance treatment options for patients with unmet medical needs.
Potential Positives
- Zymeworks has announced participation in multiple prominent investor conferences, increasing visibility and engagement with the investment community.
- The FDA granted accelerated approval for Ziihera® (zanidatamab-hrii), making it the first dual HER2-targeted bispecific antibody approved for use in HER2-positive biliary tract cancer in the U.S.
- Zymeworks is advancing a robust pipeline of wholly-owned product candidates, showcasing its commitment to addressing significant unmet medical needs in oncology.
- Strategic partnerships with global biopharmaceutical companies indicate strong collaboration efforts to enhance the development and commercialization of its therapies.
Potential Negatives
- The press release does not provide any specific updates or milestones regarding the progress or results of Zymeworks’ ongoing clinical trials, which may signal a lack of recent significant developments in their pipeline.
- The announcement primarily focuses on upcoming investor conferences, which could reflect a need for increased investor engagement rather than tangible progress in their drug development efforts.
- Despite the FDA granting accelerated approval of Ziihera®, the lack of detailed information on its commercial launch or sales projections raises concerns about the company's market readiness and financial outlook.
FAQ
What upcoming investor conferences will Zymeworks participate in?
Zymeworks will attend the Oppenheimer, Citi, and B. Riley investor conferences in February 2025.
What is Zymeworks' mission?
Zymeworks aims to improve the standard of care for patients with difficult-to-treat diseases like cancer and autoimmune conditions.
What is zanidatamab?
Zanidatamab is a HER2-targeted bispecific antibody developed by Zymeworks for treating various HER2-expressing cancers.
What recent FDA approval did Zymeworks receive?
The FDA granted accelerated approval for Ziihera®, a treatment for adults with previously-treated HER2-positive biliary tract cancer.
How can I learn more about Zymeworks?
Visit Zymeworks' website at www.zymeworks.com or follow them on X for updates and information.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZYME Insider Trading Activity
$ZYME insiders have traded $ZYME stock on the open market 18 times in the past 6 months. Of those trades, 13 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $ZYME stock by insiders over the last 6 months:
- CAPITAL, LLC ECOR1 has made 13 purchases buying 1,027,880 shares for an estimated $14,420,459 and 0 sales.
- KENNETH GALBRAITH (Chair & CEO) has made 0 purchases and 2 sales selling 57,291 shares for an estimated $855,016.
- PAUL ANDREW MOORE (Chief Scientific Officer) has made 0 purchases and 2 sales selling 21,200 shares for an estimated $316,390.
- JEFFREY T L SMITH (EVP & Chief Medical Officer) sold 11,110 shares for an estimated $165,806
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZYME Hedge Fund Activity
We have seen 62 institutional investors add shares of $ZYME stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BVF INC/IL removed 1,262,065 shares (-21.5%) from their portfolio in Q3 2024, for an estimated $15,838,915
- NEXTECH INVEST LTD. added 1,113,946 shares (+inf%) to their portfolio in Q3 2024, for an estimated $13,980,022
- MORGAN STANLEY added 867,422 shares (+20.5%) to their portfolio in Q3 2024, for an estimated $10,886,146
- DEUTSCHE BANK AG\ removed 829,266 shares (-35.2%) from their portfolio in Q3 2024, for an estimated $10,407,288
- CITADEL ADVISORS LLC removed 578,574 shares (-96.5%) from their portfolio in Q3 2024, for an estimated $7,261,103
- PERCEPTIVE ADVISORS LLC added 512,309 shares (+30.7%) to their portfolio in Q3 2024, for an estimated $6,429,477
- SILVERCREST ASSET MANAGEMENT GROUP LLC removed 511,173 shares (-64.2%) from their portfolio in Q3 2024, for an estimated $6,415,221
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
- Oppenheimer 35 th Annual Healthcare Life Sciences Conference: Zymeworks’ management will participate in virtual one-on-one meetings and a fireside chat on February 11 at 11:20 am Eastern Time (ET).
- Citi's 2025 Virtual Oncology Leadership Summit: Zymeworks’ management will participate in a virtual fireside chat on February 20 at 2:00 pm ET.
-
B. Riley Securities Precision Oncology & Radiopharma Conference: Zymeworks’ management will participate in one-on-one meetings and a panel discussion on February 28 in New York, NY.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera ® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera ® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251 planned for 2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
[email protected]
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
[email protected]
